

Table SI. Mean wound area(mm²).

Treatment	Time, days					
	0	3	6	9	18	32
PI	307.2±16.3	231.9±8.6	179.4±6.0	134.3±7.2	17.9±3.4	10.5±1.0
SES-low	332.1±10.9	228.6±5.1	157.9±4.7	111.9±3.5	10.6±1.0	5.9±0.7
SES-low+G	344.8±9.5	176.8±3.6	128.8±2.3	95.1±1.5	6.5±1.9	4.8±0.6
SES-high	307.9±14.1	243.9±10.1	153.3±7.4	105.1±5.7	20.2±2.4	9.8±1.5
SES-high+G	329.2±10.1	222.2±8.3	134.1±7.9	145.3±6.3	23.8±3.2	11.9±0.3
NF	341.3±7.2	137.3±5.2	142.6±9.3	109.8±10.6	10.9±1.5	6.0±0.7
S	336.3±7.9	187.2±6.9	186.5±12.0	123.9±8.5	19.1±3.4	6.9±1.0

PI, placebo;SES: super electrolyzed solution, ; , NF: nitrofurazone, S: silver sulfadiazine; G, gel.

Table SII. Mean wound closure (%).

Comparison	Mean difference	95% CI	Adjusted P-value
Pl vs. SES-low, day 3	-6.66	-16.53 to 3.20	0.7770
Pl vs. SES-low + G, day 3	-24.20	-33.50 to -14.90	<0.0001
Pl vs. SES-high, day 3	3.73	-5.57 to 13.04	>0.9999
Pl vs. SES-high + G, day 3	-7.96	-17.27 to 1.34	0.2486
Pl vs. NF, day 3	-35.25	-44.56 to -25.95	<0.0001
Pl vs. S, day 3	-19.83	-29.70 to -9.96	<0.0001
Pl vs. SES-low, day 6	-10.85	-20.72 to -0.98	0.0124
Pl vs. SES-low + G, day 6	-21.04	-30.35 to -11.74	<0.0001
Pl vs. SES-high, day 6	-8.62	-17.93 to 0.68	0.1208
Pl vs. SES-high + G, day 6	-17.67	-26.98 to -8.37	<0.0001
Pl vs. NF, day 6	-16.61	-25.91 to -7.30	<0.0001
Pl vs. S, day 6	-2.96	-12.83 to 6.90	>0.9999
Pl vs. SES-low, day 9	-10.02	-19.88 to -0.15	0.0410
Pl vs. SES-low + G, day 9	-16.13	-26.53 to -5.73	<0.0001
Pl vs. SES-high, day 9	-9.57	-19.43 to 0.30	0.0734
Pl vs. SES-high + G, day 9	0.43	-9.44 to 10.30	>0.9999
Pl vs. NF, day 9	-11.52	-21.39 to -1.65	0.0043
Pl vs. S, day 9	-6.86	-16.72 to 3.01	0.7229
Pl vs. SES-low, day 18	-2.63	-11.93 to 6.68	>0.9999
Pl vs. SES-low + G, day 18	-3.92	-13.22 to 5.39	0.9998
Pl vs. SES-high, day 18	0.75	-8.56 to 10.05	>0.9999
Pl vs. SES-high + G, day 18	1.42	-8.45 to 11.29	>0.9999
Pl vs. NF, day 18	-2.63	-11.93 to 6.68	>0.9999
Pl vs. S, day 18	-0.14	-9.44 to 9.16	>0.9999
Pl vs. SES-low, day 32	-1.64	-10.95 to 7.66	>0.9999
Pl vs. SES-low + G, day 32	-2.02	-11.33 to 7.28	>0.9999
Pl vs. SES-high, day 32	-0.24	-9.55 to 9.06	>0.9999
Pl vs. SES-high + G, day 32	0.20	-9.67 to 10.07	>0.9999
Pl vs. NF, day 32	-1.67	-10.97 to 7.64	>0.9999
Pl vs. S, day 32	-1.37	-10.68 to 7.93	>0.9999
SES-low vs. SES-low + G, day 3	-18.00	-38.46 to -18.72	<0.0001
SES-low vs. SES-high, day 3	10.40	0.53 to 20.27	0.0242
SES-low vs. SES-high + G, day 3	-1.30	-11.17 to 8.57	>0.9999
SES-low vs. NF, day 3	-28.59	-38.46 to -18.72	<0.0001
SES-low vs. S, day 3	-13.16	-23.57 to -2.76	0.0008
SES-low vs. SES-low + G, day 6	-10.19	-20.06 to -0.32	0.0323
SES-low vs. SES-high, day 6	2.23	-7.64 to 12.10	>0.9999
SES-low vs. SES-high + G, day 6	-6.82	-16.69 to 3.05	0.7326
SES-low vs. NF, day 6	-5.76	-15.62 to 4.11	0.9489

SES-low vs. S, day 6	7.89	-2.52 to 18.29	0.5250
SES-low vs. SES-low + G, day 9	-6.11	-15.98 to 3.76	0.8998
SES-low vs. SES-high, day 9	0.45	-8.85 to 9.76	>0.9999
SES-low vs. SES-high + G, day 9	10.45	1.15 to 19.75	0.0087
SES-low vs. NF, day 9	-1.50	-10.80 to 7.80	>0.9999
SES-low vs. S, day 9	3.16	-6.14 to 12.46	>0.9999
SES-low vs. SES-low + G, day 18	-1.29	-10.60 to 8.01	>0.9999
SES-low vs. SES-high, day 18	3.37	-5.93 to 12.68	>0.9999
SES-low vs. SES-high + G, day 18	4.05	-5.82 to 13.91	0.9999
SES-low vs. NF, day 18	-0.00	-9.31 to 9.30	>0.9999
SES-low vs. S, day 18	2.49	-6.82 to 11.79	>0.9999
SES-low vs. SES-low + G, day 32	-0.38	-9.69 to 8.92	>0.9999
SES-low vs. SES-high, day 32	1.40	-7.91 to 10.70	>0.9999
SES-low vs. SES-high + G, day 32	1.84	-8.03 to 11.71	>0.9999
SES-low vs. NF, day 32	-0.03	-9.33 to 9.28	>0.9999
SES-low vs. S, day 32	0.27	-9.03 to 9.57	>0.9999
SES-low + G, vs. SES-high, day 3	27.93	18.63 to 37.24	<0.0001
SES-low + G vs. SES-high + G, day 3	16.24	6.93 to 25.54	<0.0001
SES-low + G vs. NF, day 3	-11.05	-20.36 to -1.75	0.0031
SES-low + G vs. S, day 3	4.37	-5.50 to 14.24	0.9993
SES-low + G vs. SES-high, day 6	12.42	3.12 to 21.72	0.0002
SES-low + G vs. SES-high + G, day 6	3.37	-5.93 to 12.67	>0.9999
SES-low + G vs. NF, day 6	4.44	-4.87 to 13.74	0.9974
SES-low + G vs. S, day 6	18.08	8.21 to 27.95	<0.0001
SES-low + G vs. SES-high, day 9	6.56	-3.31 to 16.43	0.8036
SES-low + G vs. SES-high + G, day 9	16.56	6.69 to 26.43	<0.0001
SES-low + G vs. NF, day 9	4.61	-5.26 to 14.48	0.9982
SES-low + G vs. S, day 9	9.27	-0.60 to 19.14	0.1044
SES-low + G vs. SES-high, day 18	4.67	-4.64 to 13.97	0.9939
SES-low + G vs. SES-high + G, day 18	5.34	-4.53 to 15.21	0.9809
SES-low + G vs. NF, day 18	1.29	-8.01 to 10.59	>0.9999
SES-low + G vs. S, day 18	3.78	-5.52 to 13.08	0.9999
SES-low + G vs. SES-high, day 32	1.78	-7.52 to 11.08	>0.9999
SES-low + G vs. SES-high + G, day 32	2.23	-7.64 to 12.09	>0.9999
SES-low + G vs. NF, day 32	0.36	-8.95 to 9.66	>0.9999
SES-low + G vs. S, day 32	0.65	-8.65 to 9.96	>0.9999
SES-high vs. SES-high + G, day 3	-11.69	-21.00 to -2.39	0.0009
SES-high 3 vs. NF, day 3	-38.99	-48.29 to -29.68	<0.0001
SES-high vs. S, day 3	-23.56	-33.43 to -13.69	<0.0001
SES-high vs. SES-high + G, day 6	-9.05	-18.35 to 0.25	0.0705
SES-high vs. NF, day 6	-7.98	-17.29 to 1.32	0.2434
SES-high vs. S, day 6	5.66	-4.21 to 15.53	0.9586
SES-high vs. SES-high + G, day 9	10.00	0.69 to 19.30	0.0179

SES-high vs. NF, day 9	-1.95	-11.26 to 7.35	>0.9999
SES-high vs. S, day 9	2.71	-6.59 to 12.01	>0.9999
SES-high vs. SES-high + G, day 18	0.67	-9.20 to 10.54	>0.9999
SES-high vs. NF, day 18	-3.38	-12.68 to 5.93	>0.9999
SES-high vs. S, day 18	-0.89	-10.19 to 8.42	>0.9999
SES-high vs. SES-high + G, day 32	0.44	-9.42 to 10.31	>0.9999
SES-high vs. NF, day 32	-1.42	-10.73 to 7.88	>0.9999
SES-high vs. S, day 32	-1.13	-10.43 to 8.18	>0.9999
SES-high + G vs. NF, day 3	-27.29	-36.59 to -17.99	<0.0001
SES-high + G vs. S, day 3	-11.87	-21.73 to -2.00	0.0024
SES-high + G vs. NF, day 6	1.07	-8.24 to 10.37	>0.9999
SES-high + G vs. S, day 6	14.71	4.84 to 24.58	<0.0001
SES-high + G vs. NF, day 9	-11.95	-21.25 to -2.65	0.0006
SES-high + G vs. S, day 9	-7.29	-16.59 to 2.02	0.4454
SES-high + G vs. NF, day 18	-4.05	-13.92 to 5.82	0.9999
SES-high + G vs. S, day 18	-1.56	-11.43 to 8.31	>0.9999
SES-high + G vs. NF, day 32	-1.87	-11.74 to 8.00	>0.9999
SES-high + G vs. S, day 32	-1.57	-11.44 to 8.30	>0.9999
NF vs. S, day 3	15.42	5.56 to 25.29	<0.0001
NF vs. S, day 6	13.64	3.77 to 23.51	<0.0001
NF vs. S, day 9	4.66	-4.64 to 13.97	0.9940
NF vs. S, day 18	2.49	-6.82 to 11.79	>0.9999
NF, day 32 vs. S, day 32	0.29	-9.01 to 9.60	>0.9999

PI: placebo; SES: superoxidized electrolyzed solution, G: gel, NF: nitrofurazone, S: silver sulfadiazine.

Table SIII. Polymorphonuclear cell count.

Treatment	Time, days			
	6	9	18	32
Pl	5.1±1.0	15.5±2.2	6.0±1.2	3.2±0.4
SES-low	4.7±0.7	6.8±0.6	6.0±0.6	3.0±0.5
SES-low + G	6.3±0.8	10.7±1.0	8.6±1.2	3.5±0.3
SES-high	6.1±0.8	14.9±1.7	10.1±1.3	4.8±0.4
SES-high + G	9.6± 2.0	16.4±1.6	5.9±0.5	3.6±0.3
NF	10.3±0.9	16.9±1.6	4.1±0.5	3.2±0.3
S	10.8±1.2	14.5±2.2	7.6±1.1	6.6±0.4

Pl, placebo;SES: superoxidized electrolyzed solution, G: gel,NF: nitrofurazone, S: silver sulfadiazine.

Table SIV. Monocyte count.

Treatment	Time, days			
	6	9	18	32
PI	21.8±5.0	95.4±8.2	40.2±4.9	17.3±2.2
SES-low	24.6±4.3	56.6±6.2	29.8±3.8	13.5±1.5
SES-low + G	26.8±4.4	66.4±6.6	30.2±2.5	14.5±1.1
SES-high	27.5±3.2	98.5±7.8	33.1±2.8	18.3±0.9
SES-high + G	41.0±7.7	101.1±5.0	32.5±2.3	20.6±2.0
NF	60.8±7.1	114.6±7.0	43.3±3.4	18.3±1.2
S	82.1±9.3	117.5±5.8	33.1±4.6	26.4±2.3

PI, placebo, SES: superoxidized electrolyzed solution, G: gel, NF: nitrofurazone; S: silver sulfadiazine.

Table SV. Mean inflammatory infiltrate.

Comparison	Mean difference	95% CI	Adjusted P-value
Pl vs. SES-low, day 6	-3.28	-32.03 to 25.48	0.9998
Pl vs. SES-low + G, day 6	-7.00	-35.76 to 21.76	0.9872
Pl vs. SES-high, day 6	-9.75	-38.51 to 19.01	0.9355
Pl vs. SES-high + G, day 6	-28.22	-56.98 to 0.53	0.0572
Pl vs. NF, day 6	-46.72	-75.48 to -17.97	0.0002
Pl vs. S, day 6	-66.81	-95.56 to -38.05	<0.0001
Pl vs. SES-low, day 9	48.47	18.07 to 78.87	0.0003
Pl vs. SES-low + G, day 9	34.67	4.27 to 65.07	0.0169
Pl vs. SES-high, day 9	-9.14	-39.54 to 21.26	0.9632
Pl vs. SES-high + G, day 9	-8.19	-38.60 to 22.21	0.9785
Pl vs. NF, day 9	-19.75	-50.15 to 10.65	0.4145
Pl vs. S, day 9	-23.00	-53.40 to 7.40	0.2436
Pl vs. SES-low, day 18	9.86	-7.59 to 27.32	0.5785
Pl vs. SES-low + G, day 18	7.03	-10.43 to 24.48	0.8657
Pl vs. SES-high, day 18	2.44	-15.01 to 19.90	0.9994
Pl vs. SES-high + G, day 18	7.44	-10.01 to 24.90	0.8317
Pl vs. NF, day 18	-1.50	-18.95 to 15.95	>0.9999
Pl vs. S, day 18	5.19	-12.26 to 22.65	0.9649
Pl vs. SES-low, day 32	3.89	-4.68 to 12.45	0.7879
Pl vs. SES-low + G, day 32	2.42	-6.15 to 10.98	0.9730
Pl vs. SES-high, day 32	-2.64	-11.20 to 5.93	0.9586
Pl vs. SES-high + G, day 32	-3.69	-12.26 to 4.87	0.8244
Pl vs. NF, day 32	-1.11	-9.68 to 7.45	0.9996
Pl vs. S, day 32	-12.67	-21.23 to -4.10	0.0009
SES-low vs. SES-low + G, day 6	-3.72	-32.48 to 25.03	0.9996
SES-low vs. SES-high, day 6	-6.47	-35.23 to 22.28	0.9915
SES-low vs. SES-high + G, day 6	-24.94	-53.70 to 3.81	0.1252
SES-low vs. NF, day 6	-43.44	-72.20 to -14.69	0.0007
SES-low vs. S, day 6	-63.53	-92.28 to -34.77	<0.0001
SES-low vs. SES-low + G, day 9	-13.81	-44.21 to 16.60	0.7877
SES-low vs. SES-high, day 9	-57.61	-88.01 to -27.21	<0.0001
SES-low vs. SES-high + G, day 9	-56.67	-87.07 to -26.27	<0.0001
SES-low vs. NF, day 9	-68.22	-98.62 to -37.82	<0.0001
SES-low vs. S, day 9	-71.47	-101.90 to -41.07	<0.0001
SES-low vs. SES-low + G, day 18	-2.83	-20.29 to 14.62	0.9986
SES-low vs. SES-high, day 18	-7.42	-24.87 to 10.04	0.8341
SES-low vs. SES-high + G, day 18	-2.42	-19.87 to 15.04	0.9994
SES-low vs. NF, day 18	-11.36	-28.82 to 6.09	0.4122
SES-low vs. S, day 18	-4.67	-22.12 to 12.79	0.9793

SES-low vs. SES-low + G, day 32	-1.47	-10.04 to 7.09	0.9980
SES-low vs. SES-high, day 32	-6.53	-15.09 to 2.04	0.2362
SES-low vs. SES-high + G, day 32	-7.58	-16.15 to 0.98	0.1115
SES-low vs. NF, day 32	-5.00	-13.57 to 3.57	0.5411
SES-low vs. S, day 32	-16.56	-25.12 to -7.99	<0.0001
SES-low + G vs. SES-high, day 6	-2.75	-31.51 to 26.01	>0.9999
SES-low + G vs. SES-high + G, day 6	-21.22	-49.98 to 7.53	0.2693
SES-low + G vs. NF, day 6	-39.72	-68.48 to -10.97	0.0022
SES-low + G vs. S, day 6	-59.81	-88.56 to -31.05	<0.0001
SES-low + G vs. SES-high, day 9	-43.81	-74.21 to -13.40	0.0013
SES-low + G vs. SES-high + G, day 9	-42.86	-73.26 to -12.46	0.0017
SES-low + G vs. NF, day 9	-54.42	-84.82 to -24.02	<0.0001
SES-low + G vs. S, day 9	-57.67	-88.07 to -27.27	<0.0001
SES-low + G vs. SES-high, day 18	-4.58	-22.04 to 12.87	0.9811
SES-low + G vs. SES-high + G, day 18	0.42	-17.04 to 17.87	>0.9999
SES-low + G vs. NF, day 18	-8.53	-25.98 to 8.93	0.7270
SES-low + G vs. S, day 18	-1.83	-19.29 to 15.62	0.9999
SES-low + G vs. SES-high, day 32	-5.06	-13.62 to 3.51	0.5283
SES-low + G vs. SES-high + G, day 32	-6.11	-14.68 to 2.45	0.3060
SES-low + G vs. NF, day 32	-3.53	-12.09 to 5.04	0.8530
SES-low + G vs. S, day 32	-15.08	-23.65 to -6.52	<0.0001
SES-high vs. SES-high + G, day 6	-18.47	-47.23 to 10.28	0.4278
SES-high vs. NF, day 6	-36.97	-65.73 to -8.22	0.0050
SES-high vs. S, day 6	-57.06	-85.81 to -28.30	<0.0001
SES-high vs. SES-high + G, day 9	0.94	-29.46 to 31.35	>0.9999
SES-high vs. NF, day 9	-10.61	-41.01 to 19.79	0.9266
SES-high vs. S, day 9	-13.86	-44.26 to 16.54	0.7847
SES-high vs. SES-high + G, day 18	5.00	-12.45 to 22.45	0.9709
SES-high vs. NF, day 18	-3.94	-21.40 to 13.51	0.9913
SES-high vs. S, day 18	2.75	-14.70 to 20.20	0.9988
SES-high vs. SES-high + G, day 32	-1.06	-9.62 to 7.51	0.9997
SES-high vs. NF, day 32	1.53	-7.04 to 10.09	0.9976
SES-high vs. S, day 32	-10.03	-18.59 to -1.46	0.0132
SES-high + G vs. NF, day 6	-18.50	-47.26 to 10.26	0.4261
SES-high + G vs. S, day 6	-38.58	-67.34 to -9.83	0.0031
SES-high + G vs. NF, day 9	-11.56	-41.96 to 18.85	0.8939
SES-high + G vs. S, day 9	-14.81	-45.21 to 15.60	0.7299
SES-high + G vs. NF, day 18	-8.94	-26.40 to 8.51	0.6820
SES-high + G vs. S, day 18	-2.25	-19.70 to 15.20	0.9996
SES-high + G vs. NF, day 32	2.58	-5.98 to 11.15	0.9626
SES-high + G vs. S, day 32	-8.97	-17.54 to -0.41	0.0350
NF vs. S, day 6	-20.08	-48.84 to 8.67	0.3300
NF vs. S, day 9	-3.25	-33.65 to 27.15	0.9999

NF vs. S, day 18	6.69	-10.76 to 24.15	0.8899
NF vs. S, day 32	-11.56	-20.12 to -2.99	0.0029

Pl, placebo, SES: superoxidized electrolyzed solution, G: gel, NF: nitrofurazone; S: silver sulfadiazine.

Table SVI. Histology analysis of early collagen with Masson staining.

A, Day 6								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	3.0±0.0	-	>0.999	>0.999	>0.999	>0.999	0.001 ^c	0.061
SES-low	3.0±0.0	>0.999	-	>0.999	>0.999	>0.999	0.001 ^c	0.061
SES-low + G	3.0±0.0	>0.999	>0.999	-	>0.999	>0.999	0.001 ^c	0.061
SES-high	3.0±0.0	>0.999	>0.999	>0.999	-	>0.999	0.001 ^c	0.061
SES-high + G	3.0±0.0	>0.999	>0.999	>0.999	>0.999	-	0.001 ^c	0.061
NF	3.6±0.1	0.001 ^c	0.001 ^c	0.001 ^c	0.001 ^c	0.001 ^c	-	0.126
S	3.3±0.12	0.061	0.061	0.061	0.061	0.061	0.126	-
B, Day 9								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	3.3±0.1	-	0.011 ^a	>0.999	>0.999	>0.999	0.001 ^c	0.001 ^c
SES-low	2.8±0.1	0.011 ^a	-	>0.999	>0.999	>0.999	0.562	>0.999
SES-low + G	3.0±0.0	>0.999	>0.999	-	>0.999	>0.999	0.006 ^b	0.011 ^a
SES-high	3.0±0.0	>0.999	>0.999	>0.999	-	>0.999	0.006 ^b	0.011 ^a
SES-high + G	3.0±0.0	>0.999	>0.999	>0.999	>0.999	-	0.006 ^b	0.011 ^a
NF	2.5±0.1	0.001 ^c	0.562	0.006 ^b	0.006 ^b	0.006 ^b	-	>0.999
S	2.6±0.2	0.001 ^c	>0.999	0.011 ^a	0.011 ^a	0.011 ^a	>0.999	-
C, Day 18								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	2.5±0.1	-	0.001 ^c	0.001 ^c	0.001 ^c	0.001 ^c	0.001 ^c	0.001 ^c
SES-low	3.0±0.1	0.001 ^c	-	>0.999	>0.999	>0.999	>0.999	>0.999
SES-low + G	3.0±0.0	0.001 ^c	>0.999	-	0.356	>0.999	>0.999	>0.999
SES-high	2.8±0.1	0.001 ^c	>0.999	0.356	-	0.356	0.356	0.356
SES-high + G	3.0±0.0	0.001 ^c	>0.999	>0.999	0.356	-	>0.999	>0.999
NF	3.0±0.0	0.001 ^c	>0.999	>0.999	0.356	>0.999	-	>0.999
S	3.0±0.0	0.001 ^c	>0.999	>0.999	0.356	>0.999	>0.999	-
D, Day 32								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	2.5±0.0	-	0.000 ^c	<0.000 ^d	0.162	>0.999	<0.001 ^d	0.632
SES-low	3.2±0.1	0.000 ^c	-	>0.999	>0.999	0.121	0.019 ^a	0.216
SES-low + G	3.3±0.1	<0.000 ^d	>0.999	-	0.285	0.036 ^a	>0.999	0.067
SES-high	2.9±0.1	0.162	0.814	0.285	-	>0.999	<0.001 ^d	>0.999
SES-high + G	2.8±0.1	>0.999	0.121 ^a	0.036 ^a	>0.999	-	<0.001 ^d	>0.999
NF	3.7±0.0	<0.000 ^d	0.019 ^a	0.067	<0.000 ^d	<0.000 ^d	-	<0.000 ^d
S	2.8±0.1	0.632	0.216	0.067	>0.999	>0.999	<0.000 ^d	-

^aP<0.05, ^bP<0.01, ^cP≤0.001, ^dP≤0.0001.PI, placebo, SES: superoxidized electrolyzed solution, G: gel,NF: nitrofurazone, S: silver sulfadiazine.

Table SVII. Histology analysis of the collagen orientation with Masson staining.

A, Day 6									
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S	
PI	2.0±0.0	-	>0.999	0.317	0.002 ^b	>0.999	0.004 ^b	>0.999	
SES-low	2.0±0.0	>0.999	-	0.317	0.002 ^b	>0.999	0.004 ^b	>0.999	
SES-low + G	2.1±0.1	0.317	0.317	-	0.009 ^b	0.317	0.019 ^a	0.317	
SES-high	2.8±0.1	0.002 ^b	0.002 ^b	0.009 ^b	-	0.002 ^b	0.288	0.002 ^b	
SES-high + G	2.0±0.0	>0.999	>0.999	0.317	0.002 ^b	-	0.004 ^b	>0.999	
NF	2.7±0.2	0.004 ^b	0.004 ^b	0.019 ^b	0.288	0.004 ^b	-	0.004 ^b	
S	2.0±0.0	>0.999	>0.999	0.317	0.002 ^b	>0.999	0.004 ^b	-	
B, Day 9									
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S	
PI	2.0±0.0	-	0.317	>0.999	>0.999	0.317	0.317	>0.999	
SES-low	2.1±0.4	0.317	-	0.317	0.317	>0.999	>0.999	0.317	
SES-low + G	2.0±0.0	>0.999	0.317	-	>0.999	0.317	0.317	>0.999	
SES-high	2.0±0.0	>0.999	0.317	>0.999	-	0.317	0.317	>0.999	
SES-high + G	2.1±0.4	0.317	>0.999	0.317	0.317	-	>0.999	0.317	
NF	2.1±0.4	0.317	>0.999	0.317	0.317	>0.999	-	0.317	
S	2.0±0.0	>0.999	0.317	>0.999	>0.999	0.317	0.317	-	
C, Day 18									
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S	
PI	2.0±0.0	-	>0.999	>0.999	>0.999	0.317	>0.999	>0.999	
SES-low	2.0±0.0	>0.999	-	>0.999	>0.999	0.317	>0.999	>0.999	
SES-low + G	2.0±0.0	>0.999	>0.999	-	>0.999	0.317	>0.999	>0.999	
SES-high	2.0±0.0	>0.999	>0.999	>0.999	-	0.317	>0.999	>0.999	
SES-high + G	2.1±0.4	0.317	0.317	0.317	0.317	-	0.317	0.317	
NF	2.0±0.0	>0.999	>0.999	>0.999	>0.999	0.317	-	>0.999	
S	2.0±0.0	>0.999	>0.999	>0.999	>0.999	0.317	>0.999	-	
D, Day 32									
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S	
PI	2.2±0.0	-	0.000 ^c	<0.000 ^d	>0.999	>0.999	>0.999	>0.999	
SES-low	3.0±0.0	0.000 ^c	-	0.011 ^a	<0.000 ^d	0.066	<0.000 ^d	<0.000 ^d	
SES-low + G	3.6±0.1	<0.000 ^d	0.011 ^a	-	<0.000 ^d	<0.000 ^d	<0.000 ^d	<0.000 ^d	
SES-high	2.0±0.0	>0.999	<0.000 ^d	<0.000 ^d	-	0.066	>0.999	>0.999	
SES-high + G	2.5±0.0	>0.999	0.066	<0.000 ^d	0.066	-	0.066	0.066	
NF	2.0±0.0	>0.999	<0.000 ^d	<0.000 ^d	>0.999	0.066	-	>0.999	
S	2.0±0.0	>0.999	<0.000 ^d	<0.000 ^d	>0.999	0.066	>0.999	-	

^aP<0.05, ^bP<0.01, ^cP≤0.001, ^dP≤0.0001. PI: placebo, SES: superoxidized electrolyzed solution, G: gel, NF: nitrofurazone; S: silver sulfadiazine.

Table SVIII. Histology analysis of mature collagen with Masson staining.

A, Day 6								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
Day 6								
PI	2.8±0.2	-	0.022 ^a	0.212	0.631	0.513	0.019 ^a	0.181
SES-low	2.1±0.2	0.022 ^a	-	0.002 ^b	0.038 ^a	0.055	<0.000 ^d	0.236
SES-low + G	3.2±0.2	0.212	0.002 ^b	-	0.619	0.060	0.222	0.017 ^a
SES-high	3.0±0.2	0.631	0.038 ^a	0.619	-	0.050	0.021 ^a	0.021 ^a
SES-high + G	2.6±0.2	0.513	0.055	0.060	0.050	-	0.002 ^b	0.619
G								
NF	3.6±0.2	0.019 ^a	<0.000 ^d	0.222	0.021 ^a	0.002 ^b	-	0.002 ^b
S	2.4±0.2	0.181	0.236	0.017 ^a	0.021 ^a	0.619	0.002 ^b	-
B, Day 9								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	1.8±0.2	-	0.022 ^a	0.002 ^b	0.008 ^b	0.282	0.304	0.107
SES-low	1.1±0.1	0.022 ^a	-	0.152	0.553	0.295	0.118	0.382
SES-low + G	1.0±0.0	0.002 ^b	0.152	-	0.317	0.037 ^a	0.090	0.300
SES-high	1.1±0.0	0.008 ^b	0.553	0.317	-	0.108	0.528	0.152
SES-high + G	1.6±0.0	0.282	0.295	0.037 ^a	0.108	-	0.291	0.050
G								
NF	1.3±0.1	0.304	0.118	0.090	0.528	0.291	-	0.152
S	1.2±0.1	0.107	0.382	0.300	0.152	0.050	0.152	-
C, Day 18								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	1.2±0.1	-	0.471	0.001 ^c	0.085	0.010 ^b	0.294	0.708
SES-low	1.3±0.1	0.471	-	0.005 ^b	0.291	0.050	0.739	0.727
SES-low + G	2.5±0.3	0.001 ^c	0.005 ^b	-	0.043 ^a	0.136	0.009 ^b	0.003 ^b
SES-high	1.6±0.1	0.085	0.291	0.043 ^a	-	0.708	0.528	0.291
SES-high + G	1.7±0.1	0.010 ^b	0.050	0.136	0.708	-	0.291	0.050
G								
NF	1.4±0.1	0.294	0.739	0.009 ^b	0.528	0.291	-	0.471
S	1.3±0.1	0.708	0.727	0.003 ^b	0.291	0.050	0.471	-
D, Day 32								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	1.1±0.0	-	0.002 ^b	0.001 ^c	>0.999	0.473	>0.999	>0.999
SES-low	1.9±0.0	0.002 ^b	-	>0.999	0.231	0.926	0.049 ^a	0.000 ^c
SES-low + G	2.0±0.0	0.001 ^c	>0.999	-	0.021 ^a	0.108	0.003 ^b	<0.000 ^d
SES-high	1.4±0.2	>0.999	0.231	0.021 ^a	-	>0.999	>0.999	0.473
SES-high + G	1.5±0.2	0.473	0.926	0.108	>0.999	-	>0.999	0.108
G								
NF	1.3±0.1	>0.999	0.049 ^a	0.003 ^b	>0.999	>0.999	-	>0.999
S	1.0±0.0	>0.999	0.000 ^c	<0.000 ^d	0.473	0.108	>0.999	-

^aP<0.05, ^bP<0.01, ^cP<0.001, ^dP<0.0001. PI: placebo, SES: superoxidized electrolyzed solution, G: gel, NF: nitrofurazone; S: silver sulfadiazine.

Table SIX. Healing score.

A, Day 6								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	16.3±0.1	-	>0.999	>0.999	>0.999	>0.999	0.544	>0.999
SES-low	16.4±0.1	>0.999	-	>0.999	>0.999	>0.999	0.768	>0.999
SES-low + G	17.5±0.1	>0.999	>0.999	-	>0.999	>0.999	>0.999	0.176
SES-high	17.4±0.1	>0.999	>0.999	>0.999	-	>0.999	>0.999	0.261
SES-high + G	16.3±0.1	>0.999	>0.999	>0.999	>0.999	-	0.287	>0.999
G								
NF	17.8±0.1	0.544	0.768	>0.999	>0.999	0.287	-	0.110
S	14.6±0.1	>0.999	>0.999	0.176	0.261	>0.999	0.110	-
B, Day 9								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	14.1±0.1	-	>0.999	>0.999	>0.999	>0.999	>0.999	0.500
SES-low	14.5±0.2	>0.999	-	>0.999	>0.999	>0.999	0.596	0.086
SES-low + G	14.9±0.0	>0.999	>0.999	-	0.987	0.987	0.106	0.011 ^a
SES-high	13.5±0.0	>0.999	>0.999	0.987	-	>0.999	>0.999	>0.999
SES-high + G	13.5±0.1	>0.999	>0.999	0.987	>0.999	-	>0.999	>0.999
G								
NF	13.3±0.1	>0.999	0.596	0.106	>0.999	>0.999	-	>0.999
S	13.0±0.1	0.500	0.086	0.011 ^a	>0.999	>0.999	>0.999	-
C, Day 18								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	15.4±0.1	-	0.500	0.011 ^a	>0.999	0.086	>0.999	>0.999
SES-low	17.3±0.0	0.500	-	>0.999	>0.999	>0.999	>0.999	>0.999
SES-low + G	18.1±0.1	0.011 ^a	>0.999	-	0.086	>0.999	0.500	>0.999
SES-high	16.7±0.1	>0.999	>0.999	0.086	-	0.500	>0.999	>0.999
SES-high + G	17.6±0.2	0.086	>0.999	>0.999	0.500	-	>0.999	>0.999
G								
NF	16.8±0.0	>0.999	>0.999	0.500	>0.999	>0.999	-	>0.999
S	17.1±0.1	>0.999	>0.999	>0.999	>0.999	>0.999	>0.999	-
D, Day 32								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	17.5±0.2	-	0.013 ^a	0.002 ^b	>0.999	>0.999	>0.999	>0.999
SES-low	20.0±0.2	0.013 ^a	-	>0.999	0.591	>0.999	>0.999	0.002 ^b
SES-low + G	20.9±0.4	0.002 ^b	>0.999	-	0.154	0.365	>0.999	0.000
SES-high	18.3±0.4	>0.999	0.591	0.154	-	>0.999	>0.999	>0.999
SES-high + G	18.6±0.3	>0.999	>0.999	0.365	>0.999	-	>0.999	>0.999
G								
NF	18.9±0.2	>0.999	>0.999	>0.999	>0.999	>0.999	-	0.430
S	17.1±0.2	>0.999	0.002 ^b	0.000	>0.999	>0.999	0.430	-

^aP<0.05, ^bP<0.01. PI: placebo, SES: superoxidized electrolyzed solution, G: gel, NF: nitrofurazone; S: silver sulfadiazine.

Table SX. Healing status.

A, Day 6								
Group	Meanscore	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	2.5±0.2	-	>0.999	>0.999	>0.999	>0.999	>0.999	>0.999
SES-low	2.7±0.1	>0.999	-	>0.999	>0.999	>0.999	>0.999	>0.999
SES-low + G	2.8±0.1	>0.999	>0.999	-	>0.999	>0.999	>0.999	>0.999
SES-high	2.8±0.1	>0.999	>0.999	>0.999	-	>0.999	>0.999	>0.999
SES-high + G	2.7±0.1	>0.999	>0.999	>0.999	>0.999	-	>0.999	>0.999
NF	2.8±0.1	>0.999	>0.999	>0.999	>0.999	>0.999	-	>0.999
S	2.3±0.2	>0.999	>0.999	>0.999	>0.999	>0.999	>0.999	-
B, Day 9								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	2.2±0.2	-	>0.999	>0.999	>0.999	>0.999	>0.999	>0.999
SES-low	2.7±0.2	>0.999	-	>0.999	>0.999	>0.999	>0.999	>0.999
SES-low + G	2.3±0.29	>0.999	>0.999	-	>0.999	>0.999	>0.999	>0.999
SES-high	2.2±0.2	>0.999	>0.999	>0.999	-	>0.999	>0.999	>0.999
SES-high + G	2.3±0.2	>0.999	>0.999	>0.999	>0.999	-	>0.999	>0.999
NF	2.3±0.2	>0.999	>0.999	>0.999	>0.999	>0.999	-	>0.999
S	2.2±0.2	>0.999	>0.999	>0.999	>0.999	>0.999	>0.999	-
C, Day 18								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	2.5±0.2	-	>0.999	>0.999	>0.999	>0.999	>0.999	>0.999
SES-low	2.5±0.2	>0.999	-	>0.999	>0.999	>0.999	>0.999	>0.999
SES-low + G	2.8±0.12	>0.999	>0.999	-	>0.999	>0.999	>0.999	>0.999
SES-high	2.7±0.1	>0.999	>0.999	>0.999	-	>0.999	>0.999	>0.999
SES-high + G	2.8±0.12	>0.999	>0.999	>0.999	>0.999	-	>0.999	>0.999
NF	2.5±0.2	>0.999	>0.999	>0.999	>0.999	>0.999	-	>0.999
S	2.5±0.2	>0.999	>0.999	>0.999	>0.999	>0.999	>0.999	-
D, Day 32								
Group	Mean score	PI	SES-low	SES-low + G	SES-high	SES-high + G	NF	S
PI	2.1±0.1	-	0.008 ^b	0.003 ^b	>0.999	>0.999	>0.999	>0.999
SES-low	2.8±0.1	0.008 ^b	-	>0.999	0.255	>0.999	>0.999	0.056
SES-low + G	2.9±0.1	0.003 ^b	>0.999	-	0.107	0.532	>0.999	0.021 ^a
SES-high	2.3±0.1	>0.999	0.255	0.107	-	>0.999	>0.999	>0.999
SES-high + G	2.4±0.1	>0.999	>0.999	0.532	>0.999	-	>0.999	>0.999
NF	2.5±0.1	>0.999	>0.999	>0.999	>0.999	>0.999	-	>0.999
S	2.2±0.1	>0.999	0.056	0.021 ^a	>0.999	>0.999	>0.999	-

^aP<0.05, ^bP<0.01. PI, placebo; SES: superoxidized electrolyzed solution; G: gel; NF: nitrofurazone; S: silver sulfadiazine.